Screener
Amgen AMGN Impairment Charges
Impairment Charges at other companies
Other financials
Where this comes from
Reported directly by Amgen in its filing.
Tagged under the XBRL concept us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill.
The source filing: Amgen’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 7:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000318154-26-000057
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Net income | $1,819 | $1,730 |
| Noncash adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation, amortization and other | 1,116 | 1,387 |
| Impairment of intangible assets | — | 800 |
| Stock-based compensation expense | 75 | 85 |
| Deferred income taxes | (176) | (250) |
| Loss (gain) on equity securities | 143 | (1,295) |
| Other items, net | (67) | (50) |
Item 1. FINANCIAL STATEMENTS
FAQ
- What is Amgen's impairment charges?
- Amgen (AMGN) reported impairment charges of $0 in Q1 2026.
- How has Amgen's impairment charges changed year-over-year?
- Amgen's impairment charges decreased by 100.0% year-over-year, from $800M to $0.
- What does impairment charges mean?
- Non-cash asset impairment charges added back in the operating cash flow reconciliation since they don't represent cash outflows.
Ask your AI about Amgen's impairment charges.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude